Skip to content

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

The Clinical Outcomes and Artificial Intelligence Prediction Model of Ultrasound-guided Thermal Ablation for the Treatment of Low-risk Papillary Thyroid Carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06316895
Enrollment
3772
Registered
2024-03-19
Start date
2024-04-01
Completion date
2029-12-31
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary Thyroid Cancer

Brief summary

1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma; 2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma;

Interventions

PROCEDUREthyroid surgery

thyroid lobectomy

radiofrequency ablation; microwave ablation or laser ablation

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. patients age between 18 and 80 year old, both sex 2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration 3. the largest diameter ≤2.0 cm 4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, nech and chest CT 5. follow-up period ≥12 months,

Exclusion criteria

1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy 2. history of neck radiation 3. history of thyroid surgery 4. coagulation disorder 5. serious heart, respiratory, liver, or renal failure 6. dysfunction of the vocal cord on the opposite side

Design outcomes

Primary

MeasureTime frameDescription
rate of disease progressionmore than 5 yearcervical lymph node metastases, recurrent tumors and persistent tumors

Secondary

MeasureTime frameDescription
Rate of complications1weeksurgery or ablation complications
Rate of tumor disappearance2 yearcomplete disappearance of ablated tumor on ultrasound and contrast-enhanced ultrasound

Countries

China

Contacts

CONTACTLin Yan, MD
gemma-y@163.com13811237313
STUDY_CHAIRYukun Luo

Chinese PLA General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026